홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Ibandronate

HCID 60852
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
114084-78-5
표준 SMILES
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
분자식
C9H23NO7P2
평균 분자량
319.23 g/mol
단동위원소 질량
319.09497607

개요

Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid]. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA approval on 16 May 2003.

이름 및 식별자

우선 이름
Ibandronate
IUPAC
[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid
영어명
Ibandronic acid
분자식
C9H23NO7P2
분자량
319.23

이름 및 동의어

Ibandronic AcidIbandronate114084-78-5BondenzaIasibon{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acidIbandronic Acid TevaIbandronic Acid AccordIbandronic Acid Sandoz[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acidAcido ibandronicoacide ibandronique
이름 더 보기
IbandronicBPH 24Ibadronic AcidIbandronate AcidIBANDRONIC ACID-D3Tirofiban Impurity 67Ibandronic acid USP/EP/BPIbandronic Acid (Ibandronate)[1-Hydroxy-3-(MethylpentylaMino)propylidene]diphosphonic Acid
UMD7G2653WNSC-722623DTXSID5048340RPR-102289AQuodixor(1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonic acidacidum ibandronicumRefChem:56785

데이터베이스 식별자

CAS
114084-78-5

물성

구조 계산 물성

XLogP
-4.1
극성 표면적
139 Ų
수소 결합 공여자 수
5
수소 결합 수용자 수
8
회전 가능 결합 수
9
무거운 원자 수
19
형식 전하
0
복잡도
342

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-2.1
Solubility · 2건

Freely soluble

1.34e+01 g/L

Human Drugs · 6건

Breast Feeding; Lactation; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

Melting Point113-115
Physical DescriptionSolid
Collision Cross Section170.12 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
113 · 113-115°C
끓는 점
587.8 · 587.8±60.0 °C(Predicted)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (95.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (95.2%)

독성 정보

Exposure RoutesPoorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
Toxicity Summary · 1건

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Signs and SymptomsLD<sub>50</sub> = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

화학 및 산업

약리 정보

ATC Code · 2건

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingIbandronate's protein binding in serum varies from 85.7-99.5% over a concentration of 0.5-10ng/mL, but is generally 86% across a concentration range of 20-2000ng/mL.
Pharmacodynamics · 1건

Ibandronate is a nitrogen containing bisphosphonate used to treat and prevent osteoporosis in postmenopausal women. The therapeutic index is wide as overdoses are not especially toxic, and the duration of action is long as the half life can be up to 157 hours. Patients should be counselled regarding the risk of upper GI adverse reactions, hypocalcemia, musculoskeletal pain, osteonecrosis of the jaw, atypical fractures of the femur, and severe renal impairment.

Mechanism of Action · 1건

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as ibandronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. ibandronate also activated caspase-3 which contribute to apoptosis.

Biological Half-LifeThe half life of ibandronate in postmenopausal women ranges from 37-157 hours.
Metabolism/Metabolites · 2건

Ibanronate is not metabolized in humans.

관련 반응

36건
반응 기록 만들기
HRID 229896 반응식
HRID 229896반응물로
HRID 229897 반응식
HRID 229897반응물로
HRID 229898 반응식
HRID 229898반응물로
HRID 229899 반응식
HRID 229899반응물로
HRID 229900 반응식
HRID 229900반응물로
HRID 229901 반응식
HRID 229901반응물로
HRID 229902 반응식
HRID 229902반응물로
HRID 229903 반응식
HRID 229903반응물로
이전1 / 5 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
PubChem CID
60852
DTXSID
DTXSID5048340
ChEMBL
CHEMBL997
UNII
UMD7G2653W
EC Number
688-095-0
Nikkaji
J476.066B
밀도
1.449 · 1.449±0.06 g/cm3(Predicted)
저장 조건
-20 °C · Sealed in dry,Store in freezer, under -20°C
용해도
수용성 염기(약간 용해됨), 메탄올(약간 용해됨), 물(약간 용해됨)
산도 계수 (pKa)
1.6 · 1.60±0.10(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지
안정성
흡습성
InChI
InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)
InChIKey
MPBVHIBUJCELCL-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CCN(C)CCCCC
EPA
1 · Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis- (114084-78-5)

화학적 성질

White Solid

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

ibandronate

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub> = 811 mg/kg (rat, oral)

안전 데이터

신호 어
Warning
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H302

No evidence of ibandronate being metabolized in humans. Route of Elimination: Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces. Half Life: 10-60 hours

FDA Pharmacological Classification · 5건

UMD7G2653W

IBANDRONIC ACID

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Ibandronic acid is a Bisphosphonate.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 4건

Oral ibandronate is 0.63% bioavailable. In a study of healthy males, a 10mg oral dose had a Tmax of 1.1±0.6h and a Cmax of 4.1±2.6ng/mL. The Tmax is approximately 1 hour, while Cmax varies depending on dose. A 2mg intravenous dose of ibandronate has an AUC of 316ng\*h/mL, a 4mg intravenous dose of ibandronate has an AUC of 581ng\*h/mL, and a 6mg intravenous dose of ibandronate has an AUC of 908ng\*h/mL.

Ibandronate is predominantly eliminated in the urine and the unabsorbed drug is eliminated unchanged in the feces.

The apparent terminal volume of distribution of ibandronate is 90-368L in headlthy subjects and 103L in postmenopausal women with osteopenia.

The total clearance of ibandronate is 84-160mL/min.

Cellular LocationsCytoplasm
Metabolite PathwaysIbandronate Action Pathway

용도 및 제조

Uses · 2건

Use (kg; approx.) in Germany (2009): >100

For the treatment and prevention of osteoporosis in postmenopausal women.

응용 분야 · 2건

개요This third generation biphosphonate was launched in Austria and Germany for the treatment of bone disorders such as hypercalcemia in malignancy and ostedysis, Paget's disease and osteoporosis. It does not effect bone mineralization, therefore, the potential risk of osteomalacia is prevented. This was a problem with first generation derivatives. While the exact mode of action is not understood, they are inhibitors of osteroclast mediated bone resorption. These compounds strongly interact with hydroxyapatite crystals and have a half-life in the skeleton of several years. Despite this observation ibandronate was well tolerated and safe.

용도A biphosphonate bone resorption inhibitor.

상·하류 제품 정보

하류 제품

Ibandronate sodium monohydrate